Physician profile
Steven Gene Wong
NPI 1275553307
$96,475.31
in general payments reported to CMS, 2019-2025
62 companies · $1,136 in 2025
The $1,136 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $56K · 2020: $33K · 2021: $1,748 · 2022: $1,405 · 2023: $1,301 · 2024: $1,377 · 2025: $1,136.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,635 · Education: $180.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,634.79 |
| Education | $179.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verastem, INC. | $78,848.61 | 2019-2020 | |
| Rigel Pharmaceuticals, INC. | $3,209.87 | 2019-2021 | |
| Seagen INC. | $3,010.02 | 2020-2023 | Adcetris |
| E.R. Squibb & Sons, L.L.C. | $816.90 | 2019-2024 | Opdivo |
| Astrazeneca Pharmaceuticals Lp | $753.68 | 2019-2024 | Enhertu, Lynparza |
| Astellas Pharma US INC | $728.32 | 2019-2024 | Padcev |
| Merck Sharp & Dohme LLC | $701.06 | 2019-2025 | Keytruda, Lynparza |
| Bayer Healthcare Pharmaceuticals INC. | $663.87 | 2019-2024 | |
| Incyte Corporation | $658.33 | 2019-2024 | Jakafi |
| Genentech USA, INC. | $572.32 | 2019-2020 | |
| Pfizer INC. | $552.52 | 2019-2025 | |
| Genzyme Corporation | $532.69 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $464.43 | 2019-2025 | |
| Janssen Scientific Affairs, LLC | $345.22 | 2024-2025 | Erleada |
| Janssen Biotech, INC. | $306.05 | 2019-2023 |
Show all 62 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $300.12 | 2022-2025 | Enhertu |
| Dendreon Pharmaceuticals LLC | $272.94 | 2019-2022 | |
| Amgen INC. | $268.25 | 2019-2023 | Lumakras |
| Epizyme, INC. | $238.52 | 2020-2021 | |
| Aadi Bioscience, INC. | $218.72 | 2022-2024 | Fyarro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $198.73 | 2020-2025 | Gilotrif |
| Lilly USA, LLC | $181.50 | 2021-2025 | Jaypirca, Verzenio, Retevmo |
| Tempus Ai, INC | $175.29 | 2025 | Xt Cdx |
| Array Biopharma INC | $160.79 | 2019-2025 | Braftovi, Mektovi, Lorbrena |
| Takeda Pharmaceuticals U.S.A., INC. | $155.91 | 2019-2024 | Alunbrig, Fruzaqla, Ninlaro |
| West Therapeutics Development, LLC | $145.77 | 2019-2020 | |
| Taiho Oncology, INC. | $145.20 | 2020-2022 | |
| Beigene USA, INC. | $126.49 | 2021-2024 | Brukinsa |
| Celgene Corporation | $125.91 | 2019-2022 | |
| Coherus Oncology, INC. | $122.01 | 2020-2025 | Loqtorzi |
| Exelixis INC. | $109.09 | 2019-2023 | Cabometyx |
| Ipsen Biopharmaceuticals, INC | $108.56 | 2019-2025 | Tazverik |
| Karyopharm Therapeutics INC. | $99.44 | 2020-2022 | |
| Puma Biotechnology, INC. | $97.61 | 2019-2020 | |
| Abbvie INC. | $95.61 | 2019-2025 | |
| Heron Therapeutics, INC. | $90.56 | 2019-2022 | |
| Eisai INC. | $85.70 | 2019-2021 | |
| Gilead Sciences, INC. | $76.82 | 2021-2023 | Trodelvy |
| Spectrum Pharmaceuticals INC. | $67.97 | 2023-2025 | Rolvedon |
| Deciphera Pharmaceuticals INC. | $67.79 | 2024-2025 | Qinlock, Romvimza |
| Helsinn Therapeutics (U.S.), INC. | $51.49 | 2019-2024 | Akynzeo |
| Kyowa Kirin, INC. | $49.38 | 2019 | |
| Tolmar Pharmaceuticals, INC. | $47.00 | 2021-2022 | |
| Glaxosmithkline, LLC. | $46.99 | 2022-2023 | Zejula, Jemperli |
| Sun Pharmaceutical Industries INC. | $36.26 | 2020 | |
| Tersera Therapeutics LLC | $34.70 | 2022 | |
| Janssen Pharmaceuticals, INC | $28.73 | 2019 | |
| Baxter Healthcare | $27.93 | 2024 | Hillrom - Volara System |
| Stemline Therapeutics INC. | $25.49 | 2021 | |
| Alnylam Pharmaceuticals INC. | $23.82 | 2022 | |
| Amag Pharmaceuticals, INC. | $23.69 | 2020 | |
| Pharmaessentia USA Corporation | $22.03 | 2025 | Besremi |
| Morphosys, US INC. | $20.74 | 2023 | Monjuvi |
| Eusa Pharma (US) LLC | $20.24 | 2020 | |
| Beone Medicines USA, INC. | $18.62 | 2025 | Brukinsa |
| Emd Serono, INC. | $17.76 | 2021 | |
| Alfasigma USA, INC. | $17.36 | 2020 | |
| Cumberland Pharmaceuticals, INC. | $14.63 | 2024 | Sancuso |
| Terumo Bct, INC. | $14.25 | 2019 | |
| Alexion Pharmaceuticals, INC. | $14.07 | 2020 | |
| Fortovia Therapeutics, INC. | $10.80 | 2020 | |
| Organon LLC | $10.14 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Wong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.